1
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar
|
2
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
3
|
Rask-Andersen M, Almén MS and Schiöth HB:
Trends in the exploitation of novel drug targets. Nat Rev Drug
Discov. 10:579–590. 2011. View
Article : Google Scholar : PubMed/NCBI
|
4
|
Klein CA: Selection and adaptation during
metastatic cancer progression. Nature. 501:365–372. 2013.
View Article : Google Scholar : PubMed/NCBI
|
5
|
Bedard PL, Hansen AR, Ratain MJ and Siu
LL: Tumour heterogeneity in the clinic. Nature. 501:355–364. 2013.
View Article : Google Scholar : PubMed/NCBI
|
6
|
Roukos DH: Beyond HER2 and trastuzumab:
Heterogeneity, systems biology, and cancer origin research may
guide the future for personalized treatment of very early but
aggressive breast cancer. J Clin Oncol. 28:e279–e280; author reply
e282-e283. 2010. View Article : Google Scholar : PubMed/NCBI
|
7
|
Curtis C, Shah SP, Chin SF, Turashvili G,
Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, et
al METABRIC Group: The genomic and transcriptomic architecture of
2,000 breast tumours reveals novel subgroups. Nature. 486:346–352.
2012.PubMed/NCBI
|
8
|
Sørlie T, Perou CM, Tibshirani R, Aas T,
Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey
SS, et al: Gene expression patterns of breast carcinomas
distinguish tumor subclasses with clinical implications. Proc Natl
Acad Sci USA. 98:10869–10874. 2001. View Article : Google Scholar : PubMed/NCBI
|
9
|
Perou CM, Sørlie T, Eisen MB, van de Rijn
M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA,
et al: Molecular portraits of human breast tumours. Nature.
406:747–752. 2000. View
Article : Google Scholar : PubMed/NCBI
|
10
|
Lehmann BD, Bauer JA, Chen X, Sanders ME,
Chakravarthy AB, Shyr Y and Pietenpol JA: Identifcation of human
triple-negative breast cancer subtypes and preclinical models for
selection of targeted therapies. J Clin Invest. 121:2750–2767.
2011. View
Article : Google Scholar : PubMed/NCBI
|
11
|
Prat A, Parker JS, Karginova O, Fan C,
Livasy C, Herschkowitz JI, He X and Perou CM: Phenotypic and
molecular characterization of the claudin-low intrinsic subtype of
breast cancer. Breast Cancer Res. 12:R682010. View Article : Google Scholar : PubMed/NCBI
|
12
|
Russnes HG, Vollan HK, Lingjaerde OC,
Krasnitz A, Lundin P, Naume B, Sørlie T, Borgen E, Rye IH, Langerød
A, et al: Genomic architecture characterizes tumor progression
paths and fate in breast cancer patients. Sci Transl Med. 2:38–47.
2010.
|
13
|
Johnson JI, Decker S, Zaharevitz D,
Rubinstein LV, Venditti JM, Schepartz S, Kalyandrug S, Christian M,
Arbuck S, Hollingshead M, et al: Relationships between drug
activity in NCI preclinical in vitro and in vivo models and early
clinical trials. Br J Cancer. 84:1424–1431. 2001. View Article : Google Scholar : PubMed/NCBI
|
14
|
de Azambuja E, Cardoso F, de Castro G Jr,
Colozza M, Mano MS, Durbecq V, Sotiriou C, Larsimont D,
Piccart-Gebhart MJ and Paesmans M: Ki-67 as prognostic marker in
early breast cancer: A meta-analysis of published studies involving
12,155 patients. Br J Cancer. 96:1504–1513. 2007. View Article : Google Scholar : PubMed/NCBI
|
15
|
Li FY, Wu SG, Zhou J, Sun JY, Lin Q, Lin
HX, Guan XX and He ZY: Prognostic value of Ki-67 in breast cancer
patients with positive axillary lymph nodes: A retrospective cohort
study. PLoS One. 9:e872642014. View Article : Google Scholar : PubMed/NCBI
|
16
|
Stuart-Harris R, Caldas C, Pinder SE and
Pharoah P: Proliferation markers and survival in early breast
cancer: A systematic review and meta-analysis of 85 studies in
32,825 patients. Breast. 17:323–334. 2008. View Article : Google Scholar : PubMed/NCBI
|
17
|
Urruticoechea A, Smith IE and Dowsett M:
Proliferation marker Ki-67 in early breast cancer. J Clin Oncol.
23:7212–7220. 2005. View Article : Google Scholar : PubMed/NCBI
|
18
|
Jalava P, Kuopio T, Juntti-Patinen L,
Kotkansalo T, Kronqvist P and Collan Y: Ki67 immunohistochemistry:
a valuable marker in prognostication but with a risk of
misclassification: proliferation subgroups formed based on Ki67
immunoreactivity and standardized mitotic index. Histopathology.
48:674–682. 2006. View Article : Google Scholar : PubMed/NCBI
|
19
|
Cheang MC, Chia SK, Voduc D, Gao D, Leung
S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, et al: Ki67
index, HER2 status, and prognosis of patients with luminal B breast
cancer. J Natl Cancer Inst. 101:736–750. 2009. View Article : Google Scholar : PubMed/NCBI
|
20
|
Pietras K and Ostman A: Hallmarks of
cancer: Interactions with the tumor stroma. Exp Cell Res.
316:1324–1331. 2010. View Article : Google Scholar : PubMed/NCBI
|
21
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
22
|
Moreth K, Brodbeck R, Babelova A, Gretz N,
Spieker T, Zeng-Brouwers J, Pfeilschifter J, Young MF, Schaefer RM
and Schaefer L: The proteoglycan biglycan regulates expression of
the B cell chemoattractant CXCL13 and aggravates murine lupus
nephritis. J Clin Invest. 120:4251–4272. 2010. View Article : Google Scholar : PubMed/NCBI
|
23
|
Merline R, Moreth K, Beckmann J, Nastase
MV, Zeng-Brouwers J, Tralhão JG, Lemarchand P, Pfeilschifter J,
Schaefer RM, Iozzo RV, et al: Signaling by the matrix proteoglycan
decorin controls inflammation and cancer through PDCD4 and
MicroRNA-21. Sci Signal. 4:ra752011. View Article : Google Scholar : PubMed/NCBI
|
24
|
Alghisi GC, Ponsonnet L and Rüegg C: The
integrin antagonist cilengitide activates alphaVbeta3, disrupts
VE-cadherin localization at cell junctions and enhances
permeability in endothelial cells. PLoS One. 4:e44492009.
View Article : Google Scholar : PubMed/NCBI
|
25
|
Krumdieck CL, dos Santos JE and Ho KJ: A
new instrument for the rapid preparation of tissue slices. Anal
Biochem. 104:118–123. 1980. View Article : Google Scholar : PubMed/NCBI
|
26
|
Hood CJ and Parham DM: A simple method of
tumour culture. Pathol Res Pract. 194:177–181. 1998. View Article : Google Scholar : PubMed/NCBI
|
27
|
van der Kuip H, Mürdter TE, Sonnenberg M,
McClellan M, Gutzeit S, Gerteis A, Simon W, Fritz P and Aulitzky WE
and Aulitzky WE: Short term culture of breast cancer tissues to
study the activity of the anticancer drug taxol in an intact tumor
environment. BMC Cancer. 6:86–92. 2006. View Article : Google Scholar : PubMed/NCBI
|
28
|
Milani C, Katayama ML, de Lyra EC, Welsh
J, Campos LT, Brentani MM, Maciel MS, Roela RA, del Valle PR, Góes
JC, et al: Transcriptional effects of 1,25 dihydroxyvitamin D(3)
physiological and supra-physiological concentrations in breast
cancer organotypic culture. BMC Cancer. 13:1192013. View Article : Google Scholar : PubMed/NCBI
|
29
|
Holliday DL, Moss MA, Pollock S, Lane S,
Shaaban AM, Millican-Slater R, Nash C, Hanby AM and Speirs V: The
practicalities of using tissue slices as preclinical organotypic
breast cancer models. J Clin Pathol. 66:253–255. 2013. View Article : Google Scholar
|
30
|
Grosso SH, Katayama ML, Roela RA, Nonogaki
S, Soares FA, Brentani H, Lima L, Folgueira MA, Waitzberg AF,
Pasini FS, et al: Breast cancer tissue slices as a model for
evaluation of response to rapamycin. Cell Tissue Res. 352:671–684.
2013. View Article : Google Scholar : PubMed/NCBI
|
31
|
Gerlach MM, Merz F, Wichmann G, Kubick C,
Wittekind C, Lordick F, Dietz A, Bechmann I and Waitzberg AF: Slice
cultures from head and neck squamous cell carcinoma: A novel test
system for drug susceptibility and mechanisms of resistance. Br J
Cancer. 110:479–488. 2014. View Article : Google Scholar :
|
32
|
Goldhirsch A, Ingle JN, Gelber RD, Coates
AS, Thürlimann B and Senn HJ: Panel members: Thresholds for
therapies: Highlights of the St Gallen International Expert
Consensus on the primary therapy of early breast cancer 2009. Ann
Oncol. 20:1319–1329. 2009. View Article : Google Scholar : PubMed/NCBI
|